Plain answer: These were two different head-to-head trials, not a repeat test with opposite answers. In REDEFINE 4, adults with obesity received a higher CagriSema combination dose or tirzepatide 15 mg for 84 weeks. CagriSema did not meet the trial’s primary goal of showing that its weight-loss effect was non-inferior to tirzepatide. In REIMAGINE 5, adults with type 2 diabetes received lower comparison doses for 60 weeks. The sponsor reported greater average weight loss with CagriSema 1.0 mg/1.0 mg than with tirzepatide 5 mg, while the blood-sugar reduction met its non-inferiority goal. The different participants, doses, follow-up times, and outcome analyses limit what can be concluded by placing the percentages side by side.
The two comparisons at a glance
| Question | REDEFINE 4 | REIMAGINE 5 |
|---|---|---|
| Who was studied? | 809 randomized adults with obesity and at least one related condition | Adults with type 2 diabetes inadequately controlled on metformin, an SGLT2 inhibitor, or both |
| What was compared? | CagriSema 2.4 mg cagrilintide + 2.4 mg semaglutide versus tirzepatide 15 mg | CagriSema 1.0 mg cagrilintide + 1.0 mg semaglutide versus tirzepatide 5 mg |
| When were the main results measured? | Week 84 | Week 60 |
| Weight change if participants adhered to treatment (efficacy estimand) | 23.0% loss with CagriSema versus 25.5% with tirzepatide | 12.4% loss with CagriSema versus 9.1% with tirzepatide |
| Weight change regardless of treatment adherence (treatment-regimen estimand) | 20.2% loss with CagriSema versus 23.6% with tirzepatide | Not given in the September 2026 topline announcement |
| What did the planned comparison conclude? | Did not demonstrate non-inferiority for weight loss | Reported superiority for weight loss and non-inferiority for HbA1c reduction |
What happened in REDEFINE 4?
REDEFINE 4 was an open-label trial, so participants and investigators knew which treatment was assigned. Novo Nordisk reported 23.0% average weight loss with CagriSema 2.4 mg/2.4 mg and 25.5% with tirzepatide 15 mg under the efficacy estimand at week 84. Under the treatment-regimen estimand, which asks about the effect regardless of adherence, the reported figures were 20.2% and 23.6%. The trial did not meet its primary non-inferiority endpoint. That means it did not establish, under its preplanned statistical rule, that CagriSema’s weight-loss effect was close enough to tirzepatide’s. It does not mean CagriSema caused no weight loss.
What happened in REIMAGINE 5?
REIMAGINE 5 asked a different question in people with type 2 diabetes. At week 60, the sponsor reported estimated average weight loss of 12.4% with CagriSema 1.0 mg/1.0 mg and 9.1% with tirzepatide 5 mg, a result it described as superior for weight loss. HbA1c, a measure of longer-term blood-sugar control, fell by 1.71 percentage points with CagriSema and 1.67 with tirzepatide; the sponsor described that outcome as non-inferior. The two primary endpoints were weight change and HbA1c change, and the topline release supplied the efficacy-estimand weight figures. The REIMAGINE 5 trial record (NCT06534411) identifies the registered study.
Why can both findings be true?
REDEFINE 4 compared 2.4 mg/2.4 mg against 15 mg in adults with obesity over 84 weeks. REIMAGINE 5 compared 1.0 mg/1.0 mg against 5 mg in adults with type 2 diabetes over 60 weeks. The conditions, comparison doses, and timing changed together. In REDEFINE 4, the published headline also shifts depending on whether the efficacy or treatment-regimen estimand is used. It is therefore invalid to treat the difference between 23.0% and 12.4% as a measured change caused by CagriSema dose alone, or to say the two studies established a universal winner between CagriSema and tirzepatide.
What is an estimand?
An estimand is the precise treatment effect a trial’s analysis aims to estimate. For example, REDEFINE 4 reported an efficacy estimand asking what the effect would be if everyone adhered to assigned treatment, and a treatment-regimen estimand asking about the effect regardless of adherence. Both are valid questions, but their results should keep their labels. Read our REDEFINE 9 guide for another example of why a trial can report more than one weight-loss percentage.
What remains uncertain?
These head-to-head numbers come from sponsor topline announcements. A full published report can provide more detail on missing data, confidence intervals, adverse events, and subgroup results. The REIMAGINE 5 announcement says CagriSema was generally well tolerated, but the weight percentages alone cannot rank overall safety. Neither comparison establishes an individual’s likely response, and neither validates a separately sold research vial as the clinical trial product.
As of this November 19, 2026 source check, Novo Nordisk described CagriSema as investigational and not approved for use in the United States. A trial result does not establish the identity, sterility, or suitability for human use of an online research blend.
Quick answers
Did CagriSema beat tirzepatide?
In REIMAGINE 5, the sponsor reported superior weight loss for CagriSema 1.0 mg/1.0 mg versus tirzepatide 5 mg in adults with type 2 diabetes. In REDEFINE 4, CagriSema 2.4 mg/2.4 mg did not demonstrate non-inferiority to tirzepatide 15 mg in adults with obesity. Say which trial and dose you mean.
Does REIMAGINE 5 prove the lower CagriSema dose works better?
No. The two CagriSema doses were not randomized against each other in these two trials. Different populations and comparator doses prevent that conclusion.
Explore the related evidence
See what each CagriSema component contributes, why REDEFINE 9 has two headline analyses, and the separate tirzepatide-versus-semaglutide head-to-head trial. Read how PeptideWhy checks and corrects sources.